Holen Sie sich die Stockscreener-App
4.225
11.24%
-0.535
Handel nachbörslich:
4.36
0.135
+3.20%
Schlusskurs vom Vortag:
$4.76
Offen:
$4.68
24-Stunden-Volumen:
555.94K
Relative Volume:
0.90
Marktkapitalisierung:
$278.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.25M
KGV:
-10.31
EPS:
-0.4099
Netto-Cashflow:
$-20.05M
1W Leistung:
-3.32%
1M Leistung:
+60.04%
6M Leistung:
+38.98%
1J Leistung:
+48.25%
1-Tages-Spanne:
$4.15
$4.71
1-Wochen-Bereich:
$4.01
$5.55
52-Wochen-Spanne:
$2.025
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Firmenname
Galectin Therapeutics Inc
Sektor
Branche
Telefon
678-620-3186
Adresse
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.225 | 313.48M | 0 | -26.25M | -20.05M | -0.4099 |
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 121.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
678.94 | 69.66B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
857.97 | 53.99B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
179.18 | 39.21B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.15 | 37.27B | 4.29B | 577.22M | 641.34M | 4.2086 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-13 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Herabstufung | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Herabstufung | ROTH Capital | Buy → Sell |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-09-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-08-01 | Herabstufung | Aegis Capital | Buy → Hold |
| 2014-07-30 | Bestätigt | MLV & Co | Buy |
| 2014-07-29 | Bestätigt | MLV & Co | Buy |
| 2014-04-02 | Bestätigt | MLV & Co | Buy |
| 2014-02-10 | Bestätigt | Aegis Capital | Buy |
| 2014-01-09 | Bestätigt | Aegis Capital | Buy |
| 2013-12-03 | Eingeleitet | MLV & Co | Buy |
| 2013-08-19 | Bestätigt | Aegis Capital | Buy |
Alle ansehen
Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten
Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock - Investing.com
Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com - Investing.com Canada
Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan - Stock Titan
Can Galectin Therapeutics (NASDAQ:GALT) Regain Confidence? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by Zacks Research - MarketBeat
Price to book forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
$Galectin Therapeutics (GALT.US)$ - Moomoo
$Galectin Therapeutics (GALT.US)$ put CMO at the table with who at solar? - Moomoo
GALT jumps 11% on FDA alignment for belapectin phase III path in MASH - MSN
Enterprise value to revenue forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Price to sales forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review
Form 4 Galectin Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock - Investing.com
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock By Investing.com - Investing.com Nigeria
Galectin Therapeutics director sells $150,890 in common stock By Investing.com - Investing.com South Africa
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity - Stock Titan
Galectin Therapeutics (GALT) CMO exits 52,037 shares in pre-planned sale - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Top 3 Health Care Stocks That May Keep You Up At Night In June - Benzinga
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Harold Shlevin files Form 144: GALT (NASDAQ) sale of 7,732 shares - Stock Titan
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2500 Growth Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Value Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Growth Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Completeness Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000 Growth Benchmark - marketscreener.com
If you're not following me on stocktwits you probably should My money is on a partnership with Madrigal - Moomoo
GALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trial - MSN
Form 144 GALECTIN THERAPEUTICS INC For: 26 June - Investing.com UK
Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 144 GALECTIN THERAPEUTICS INC For: 26 June By Investing.com - Investing.com Nigeria
GALT (NASDAQ: GALT) Rule 144 notice: Khurram Jamil reports share disposals - Stock Titan
Form 144 GALECTIN THERAPEUTICS INCORPORATED For: 26 June By Investing.com - Investing.com Canada
[144] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
GALTGalectin Therapeutics Inc Revenue Breakdown - Finviz
$Galectin Therapeutics (GALT.US)$ The FIB Strikes Again!! - Moomoo
Galectin Therapeutics Inc. Actuals & Estimates (FWB:PHPN) - TradingView
GALT Forecast — Price Target — Prediction for 2027 - TradingView
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares - Investing.com
Form 4 Galectin Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
Galectin (NASDAQ: GALT) CMO exercises options and sells 7,557 shares under 10b5-1 plan - Stock Titan
PHPN Forecast — Price Target — Prediction for 2027 - TradingView
Galectin Therapeutics(GALT) Stock Options Chain | Quotes & News - Moomoo
FDA alignment reduces risk for Galectin Therapeutics' belapectin Phase 3 trial, keeping it a buy. - Pluang
Galectin De-Risks Belapectin Path With FDA AlignmentSets Stage For Phase 3 Upside - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail
Finanzdaten der Galectin Therapeutics Inc-Aktie (GALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.36%
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):